期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
The Effect of the Early Application of Tirofiban on Acute Ischemic Stroke (AIS) after Intravenous Thrombolysis with Urokinase
1
作者 Mingfen Li 《Journal of Clinical and Nursing Research》 2023年第4期201-204,共4页
Objective:Discussion and analysis of the effect of the early application of Tirofiban on acute ischemic stroke(AIS)after intravenous thrombolysis with urokinase.Method:The subjects of this study are 40 patients with A... Objective:Discussion and analysis of the effect of the early application of Tirofiban on acute ischemic stroke(AIS)after intravenous thrombolysis with urokinase.Method:The subjects of this study are 40 patients with AIS admitted at the Yibin Fourth People’s Hospital,of which were computer-randomized into a control group(20 cases,with regular urokinase intravenous thrombolysis therapy)and a research group(20 cases,combined with early Tirofiban treatment)from January 2018 to December 2022.The intervention outcomes between these two groups were compared and analyzed.Result:The blood platelet-related parameters before treatment had no statistical difference between the two groups(P>0.05),but the research group was higher than that of the control group after treatment(P<0.05).The Barthel index before treatment in both groups had no statistical difference(P>0.05),but the research group was higher than that of the control group after treatment(P<0.05).Conclusion:Early Tirofiban treatment for patients with AIS after intravenous thrombolysis with urokinase could effectively regulate the blood platelet-related parameters,hence improving treatment benefits and living capacity for patients,with definite clinical benefits. 展开更多
关键词 Acute ischemic stroke Intravenous thrombolysis with urokinase Tirofiban Treatment effect
下载PDF
The intra-neuroendoscopic technique: a new method for rapid removal of acute severe intraventricular hematoma 被引量:10
2
作者 Bo Du Ai-Jun Shan +4 位作者 Yu-Juan Zhang Jin Wang Kai-Wen Peng Xian-Liang Zhong Yu-Ping Peng 《Neural Regeneration Research》 SCIE CAS CSCD 2018年第6期999-1006,共8页
The mortality rate of acute severe intraventricular hematoma is extremely high, and the rate of disability in survivors is high. Intraventricular hematoma has always been a difficult problem for clinical treatment. Al... The mortality rate of acute severe intraventricular hematoma is extremely high, and the rate of disability in survivors is high. Intraventricular hematoma has always been a difficult problem for clinical treatment. Although minimally invasive endoscopic hematoma evacuation is widely used to treat this disease, the technique still has room for improvement. Equipment for the intra-neuroendoscopic technique(INET) consists of two of our patented inventions: a transparent sheath(Patent No. ZL 200820046232.0) and a hematoma aspirator(Patent No. ZL 201520248717.8). This study explored the safety and efficacy of INET by comparing it with extraventricular drainage in combination with urokinase thrombolytic therapy. This trial recruited 65 patients with severe intraventricular hemorrhage, including 35(19 men and 16 women, aged 53.2 ± 8.7 years) in the INET group and 30(17 men and 13 women, aged 51.5 ± 7.9 years) in the control group(extraventricular drainage plus urokinase thrombolytic therapy). Our results showed that compared with the control group, the INET group exhibited lower intraventricular hemorrhage volumes, shorter intensive care-unit monitoring and ventricular drainage-tube placement times, and fewer incidences of intracranial infection, secondary bleeding, and mortality. Thus, the prognosis of survivors had improved remarkably. These findings indicate that INET is a safe and efficient new method for treating severe intraventricular hematoma. This trial was registered with Clinical Trials.gov(NCT02515903). 展开更多
关键词 nerve regeneration ventricular hemorrhage transparent sheath extraventricular drainage minimally invasive surgery intra-neuroendoscopic technique urokinase thrombolysis prognosis neural regeneration
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部